U.S. FDA approves Bayer & #8217;s Xarelto ® for patients with coronary or peripheral artery disease (for specialized target groups only)

Xarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group / Approval in the U.S. follows regulatory clearance in both Europe and Canada
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news